期刊
IMMUNOLOGICAL REVIEWS
卷 280, 期 1, 页码 175-193出版社
WILEY
DOI: 10.1111/imr.12581
关键词
adaptive immunity; cancer; CD8(+) T cells; chemotherapy; innate immunity; STING
类别
资金
- H2020 European Research Council [677251]
- Fondation de France
- Fondation ARC pour la recherche sur le cancer
- Institut Merieux
- Conseil Regional de Bourgogne
- FEDER
- Agence Nationale de la Recherche [ANR-13-JSV3-0001, ANR-11-LABX-0021]
- Agence Nationale de la Recherche (ANR) [ANR-13-JSV3-0001] Funding Source: Agence Nationale de la Recherche (ANR)
- European Research Council (ERC) [677251] Funding Source: European Research Council (ERC)
Endogenous danger signals are molecules normally present in a given cell compartment that are rapidly released following cell stress and induce immune responses. We and others have shown that dying tumor cells treated with some chemotherapies are able to induce anticancer immune responses, which rely on their release of danger signals such as the nuclear protein HMGB1. DNA can also be released from chemotherapy-treated tumor cells, act as a danger signal, and boost anticancer immunity. While the immunostimulatory properties of DNA have been identified for decades, the recent discovery of a novel family of receptors, cytosolic DNA sensors, has provided a novel impetus not only to understand how chemotherapy can trigger anticancer immune responses but also to exploit DNA-derived molecules for therapeutic use. We will here discuss the molecular characteristics of endogenous danger signals released from chemotherapy-treated tumor cells and focus on the clinical relevance of using these danger signals in chemoimmunotherapeutic strategies against cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据